Colchicine Dosing for Gout
For acute gout flares, use low-dose colchicine: 1.2 mg (two 0.6 mg tablets) immediately, followed by 0.6 mg one hour later, initiated within 12 hours of symptom onset. For prophylaxis during urate-lowering therapy, use 0.5-1 mg daily for at least 6 months 1.
Acute Gout Flare Treatment
Standard Dosing (Normal Renal/Hepatic Function)
- Loading dose: 1 mg followed by 0.5 mg one hour later (EULAR) 1
- Alternative FDA-approved: 1.2 mg followed by 0.6 mg one hour later (total 1.8 mg over 1 hour) 2, 3
- Maximum dose: Do not exceed 1.8 mg in the first hour
- Timing is critical: Must initiate within 12 hours of flare onset for optimal efficacy 1
- Do not repeat: Treatment course should not be repeated for at least 3 days 3
The evidence strongly supports low-dose regimens. A pivotal 2010 randomized controlled trial demonstrated that low-dose colchicine (1.8 mg over 1 hour) achieved 37.8% response rate versus 15.5% for placebo, with a safety profile indistinguishable from placebo, while high-dose regimens (4.8 mg over 6 hours) caused significantly more gastrointestinal toxicity without additional benefit 4.
If Already on Prophylactic Colchicine
- Do not use colchicine for acute flare treatment 3
- Switch to alternative therapy (NSAID or corticosteroid) 5
Prophylaxis During Urate-Lowering Therapy
Standard Dosing
- Dose: 0.5-1 mg daily (0.6 mg once or twice daily in US) 1
- Duration: Minimum 6 months after initiating urate-lowering therapy 1
- Extended duration: Continue for 3 months after achieving target serum urate if no tophi present, or 6 months after target if tophi detected 5
Recent evidence from 2026 shows that 0.5 mg/day is as effective as 1 mg/day for preventing flares, with comparable safety profiles 6. However, the 1 mg/day dose may reduce pain intensity during breakthrough attacks 6.
Renal Impairment Adjustments
Mild Renal Impairment (CrCl 50-80 mL/min)
- Prophylaxis: No dose adjustment needed; monitor closely 3
- Acute flare: No dose adjustment needed; monitor closely 3
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Prophylaxis: 0.3 mg daily or 0.6 mg every other day 1
- Acute flare: Standard dose acceptable, but do not repeat course for at least 2 weeks 3
- Optimal dosing: 0.48 mg (if oral solution available) maintains therapeutic levels without toxicity 7
Severe Renal Impairment (CrCl 15-30 mL/min)
- Prophylaxis: 0.3 mg daily, with any dose increase requiring close monitoring 1, 3
- Acute flare: Single dose of 0.6 mg only; do not repeat for at least 2 weeks 3
- Optimal dosing: 0.3 mg daily (2.5 mL oral solution if available) 7
End-Stage Renal Disease (Dialysis)
- Prophylaxis: 0.3 mg twice weekly 5, 3
- Acute flare: Single 0.6 mg dose; do not repeat for at least 2 weeks 3
Important caveat: A 2024 study of 54 hospitalized patients with severe CKD (including 22% on dialysis) found that reduced-dose colchicine (≤0.5 mg/day in 75.8% of cases) was well-tolerated in 77% and effective in 83%, with no serious adverse events 8. This suggests colchicine can be used cautiously in severe CKD when alternatives are limited, contrary to traditional absolute contraindications.
Hepatic Impairment Adjustments
Mild to Moderate Hepatic Impairment
- Prophylaxis: No dose adjustment required; monitor closely 3
- Acute flare: No dose adjustment required; monitor closely 3
Severe Hepatic Impairment
- Prophylaxis: Consider dose reduction; monitor closely 3
- Acute flare: Consider dose reduction; monitor closely 2
Drug Interactions Requiring Dose Reduction
Strong CYP3A4 or P-glycoprotein Inhibitors
Absolute contraindication in patients with renal or hepatic impairment 1, 3
Examples: Clarithromycin, cyclosporine, ketoconazole, ritonavir, atazanavir
If no alternative available and normal organ function:
- Prophylaxis: 0.3 mg once daily 3
- Acute flare: 0.6 mg × 1 dose, followed by 0.3 mg one hour later; do not repeat for at least 3 days 3
Moderate CYP3A4 Inhibitors
Examples: Diltiazem, verapamil, erythromycin, fluconazole, grapefruit juice
Dose adjustments:
- Prophylaxis: 0.3 mg twice daily or 0.6 mg once daily 3
- Acute flare: 1.2 mg × 1 dose (do not give second dose); do not repeat for at least 3 days 3
Concurrent Statin Use
Special monitoring required: Increased risk of neuromuscular toxicity and myopathy 1
- Monitor for muscle pain, weakness, elevated creatine kinase
- Consider dose reduction in prophylaxis setting
Elderly Patients
- No specific dose adjustment in guidelines, but exercise caution 3
- Higher risk factors: More likely to have decreased renal function, polypharmacy, multiple comorbidities
- Practical approach: Start with lower prophylactic doses (0.3-0.6 mg daily) and monitor closely
- Screen carefully for drug interactions and renal function before prescribing
Critical Safety Warnings
Absolute Contraindications
- Severe renal impairment + strong CYP3A4/P-gp inhibitors 1, 3
- Hepatic impairment + strong CYP3A4/P-gp inhibitors 2, 3
First Sign of Toxicity
Diarrhea is the sentinel symptom of colchicine poisoning 9
- Immediately reduce or discontinue dose
- Gastrointestinal symptoms may progress to multiorgan failure 10
- No antidote exists; management is supportive only 10
High-Risk Populations Requiring Vigilance
- Older adults (>65 years)
- Chronic kidney disease (any stage)
- Hepatic dysfunction
- Polypharmacy (especially macrolides, azoles, statins, calcium channel blockers)
- Pediatric accidental ingestion 10
Monitoring Parameters
- Renal function: Baseline and periodic monitoring
- Drug interactions: Review all medications before prescribing
- Neuromuscular symptoms: Weakness, myalgia, elevated CK (especially with statins) 1
- Bone marrow suppression: Consider CBC in prolonged use or high-risk patients 10
Common Pitfalls to Avoid
Using high-dose regimens: The old "1.2 mg followed by 0.6 mg every hour" approach causes severe diarrhea without added benefit 4
Treating flares in patients already on prophylaxis: This doubles exposure and increases toxicity risk; switch to alternative therapy 5, 3
Ignoring drug interactions: Macrolide antibiotics (clarithromycin, erythromycin) are commonly prescribed and create dangerous interactions 1, 3
Inadequate renal dose adjustment: Even moderate renal impairment requires dose reduction for prophylaxis 7
Repeating acute treatment too soon: Wait at least 3 days (72 hours) before repeating acute treatment course, or 2 weeks in renal impairment 3
Overlooking hepatic impairment: Colchicine clearance is significantly reduced in chronic liver disease 3